Why Teva Pharmaceutical and Under Armour Are Looking So Unhealthy
In this segment from Motley Fool Money, host Chris Hill, Million Dollar Portfolio's Jason Moser, Total Income's Ron Gross, and Supernova and Rule Breakers' David Kretzmann first consider the confluence of ugliness that came together last week for Teva Pharmaceutical (NYSE: TEVA). There was an earnings miss, a guidance reduction, a dividend cut, CEO troubles, debt troubles, patent expirations, and more. Is there any good news for this massive drugmaker? And is the stock a bargain yet -- or a falling knife?
Then they dig into the issues at Under Armour (NYSE: UA) (NYSE: UAA), where a quarterly loss, lower guidance, and news of layoffs propelled the stock a new low. What can founder and CEO Kevin Plank do to get his company back to the growth that it was still enjoying just a year ago?
A full transcript follows the video.
Source: Fool.com
